Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.
Institutional and Insider Ownership
53.9% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Kiniksa Pharmaceuticals International and Zenas BioPharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiniksa Pharmaceuticals International | 0 | 1 | 8 | 0 | 2.89 |
| Zenas BioPharma | 1 | 2 | 6 | 0 | 2.56 |
Kiniksa Pharmaceuticals International presently has a consensus target price of $93.14, suggesting a potential upside of 15.29%. Zenas BioPharma has a consensus target price of $46.71, suggesting a potential upside of 65.48%. Given Zenas BioPharma’s higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Kiniksa Pharmaceuticals International.
Profitability
This table compares Kiniksa Pharmaceuticals International and Zenas BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiniksa Pharmaceuticals International | 9.59% | 13.65% | 10.09% |
| Zenas BioPharma | N/A | -122.45% | -58.04% |
Risk and Volatility
Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500.
Earnings and Valuation
This table compares Kiniksa Pharmaceuticals International and Zenas BioPharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiniksa Pharmaceuticals International | $677.56 million | 9.30 | $59.01 million | $0.97 | 83.29 |
| Zenas BioPharma | $10.00 million | 184.00 | -$377.74 million | ($8.99) | -3.14 |
Kiniksa Pharmaceuticals International has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.
Summary
Kiniksa Pharmaceuticals International beats Zenas BioPharma on 11 of the 13 factors compared between the two stocks.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
About Zenas BioPharma
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
